Paradigm Heart Failure Presentation - Lisa M. Mielniczuk, MD

Поделиться
HTML-код
  • Опубликовано: 4 дек 2024

Комментарии • 5

  • @stevehughey2247
    @stevehughey2247 4 года назад +2

    People that need Entresto usually can not afford to buy it... and insurance companies DO NOT Want to Pay For It...

  • @oldbiker9739
    @oldbiker9739 2 года назад

    so for a 2% improvement it cost more then triple . ill keep the 98 % thank you .

  • @hpdefhpdef7117
    @hpdefhpdef7117 6 лет назад +2

    This trial is a ruse, it's doing nothing more than capitalizing on the benefits of switching from an ACE inhibitor to an ARB for people with CHF and COPD.....LOL which is pretty much everyone with CHF these days! Also.....take a look at the head to head trial of valsartan vs valsartan/sacubitril, take a close look at the valsartan dosing vs entresto. Entresto is a pile of bunk, it's nothing more than an egregious attempt to overcharge for a drug they lost patent protection on. Doctors simply aren't qualified to do anything more than listen to pharma sales reps spiels. People read far too much into FDA approvals, they are not endorsements.